VRAX - שווי פעילות viraxbiolabs.com

Virax Biolabs Group (VRAX) business relies on the operation of diagnostic hubs in Asia and Britain, producing infection detection systems. The digital immunoassay environment, coupled with the ViraxClear AI service, retains B2B partners through unique data. However, niche oversaturation has led to price dumping and the liquidation of remaining inventory. This chart of the enterprise value is currently fixed at -4.50.

Demand for viral infection diagnostics and government contracts for Virax Biolabs Group (VRAX) directly determine the market attractiveness of its assets. The EV history reflects the total enterprise value by summing market capitalization and debt minus liquidity, allowing investors to assess the actual cost of acquiring the company and avoid overpaying for an inflated asset.